School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

“For ARS Pharma, 2024 marked a pivotal year, securing regulatory approvals for neffy as the first and only intranasal epinephrine treatment, laying a solid foundation for our commercial success ...

About neffy®neffy is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic ...

About neffy® neffy is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as ...

neffy is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise ...

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...